Please login to the form below

Not currently logged in

AbbVie-partnered Calico unveils first licensing deal

Google’s healthcare research business gains rights to drug prospects in neurodegeneration
calico logo

Google-backed biopharma company Calico has announced its first licensing deal, securing rights to a series of compounds aimed at preventing neurodegeneration.

Just a few days after announcing a $1.5bn partnership with AbbVie, Calico has licensed a group of neuroprotective compounds in the P7C3 class from 2M Companies, which in turn licensed them from the University of Texas Southwestern Medical Centre. 

P7C3 is actually the name of the lead candidate in the class, which have been shown to prevent cell death among neurons in some areas of the brain such as the hippocampus, leading to an overall increase in neurogenesis, or the promotion of new neurons in the brain.

Researchers working at the University led by Andrew Pieper have developed a series of analogues that have already shown activity in animal models of diseases such as Parkinson's, amyotrophic lateral sclerosis (ALS) and depression, as well as traumatic brain injury and stroke.

They are thought to exert their effects by inhibiting an enzyme called nicotinamide phosphoribosyltransferase (NAMPT), which - according to Calico - is "critical to the proper functioning and survival of cells."

Calico was set up by Google a year ago with the aim of developing drugs for "health, wellbeing and longevity", and is run by several former Genentech senior executives including Art Levinson who serves as the new company's chief executive.

The latest announcement gives the first insight into the R&D aspirations of Calico, which has been tight-lipped about the finer details of its strategy since its formations.

With the AbbVie partnership in the bag and plans afoot to establish an R&D unit focusing on age-related diseases such as neurodegeneration and cancer in the San Francisco bay area, the direction of the company is starting to become clearer.

Under the licensing deal, 2M has granted Calico an exclusive worldwide license to the P7C3 program and other NAMPT modulators in exchange for an undisclosed upfront fee, milestones, and royalty payments.

Calico's R&D head Hal Barron said: "We look forward to working with the world-leading scientists who discovered the P7C3 class of molecules to learn whether the remarkable biological effects can be translated to the treatment of human disease."

While the P7C3 programme remains in its early stages, the combined deep pockets of both AbbVie and Google should accelerate the development process.

Article by
Phil Taylor

12th September 2014

From: Research



Subscribe to our email news alerts


Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....